Elevation Oncologys personalised treatment plans for cancer ⚕️I find that the cash ($146M) vs valuation (55M) is rocket fuel for “the herd”. Also presenting itself as an “undiscovered gem” may contribute to a good ol’ pop.
They have good social media skills and their website is gorgeous. Being that this will be about as much DD as the masses ever do it can and most times is quite important for fueling said pop.
RSI in the low lows lends a little more to the “undiscovered gem” ideology even though I loath technical analysis many do not.
News about their phase II study (which they seem to be taking very seriously) should come to light within the following months and as any biotech investor knows: news + biotech = insane short term gains.
Check out my ideas on Utradea
